Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 0.1% triamcinolone CREAM Clear all
Completed Phase 2 Interventional

A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis

NCT02465606
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Encino, California • Granada Hills, California • Mission Viejo, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer

NCT05190770
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV
Interventions
Triamcinolone Acetonide, Oleogel-S10
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

NCT03011892
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib 0.15% Cream QD, Ruxolitinib 0.5% Cream QD, Ruxolitinib 1.5% Cream QD, Ruxolitinib 1.5% Cream BID, Triamcinolone 0.1% Cream BID, Vehicle Cream BID
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Birmingham, Alabama • Bryant, Arkansas • Encino, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03568318
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, Upadacitinib, Topical corticosteroids (TCS)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 75 Years
Enrollment
1,533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
59
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Not applicable Interventional Results available

Hydrogel Patch for the Treatment of Eczema

NCT00924508
View directory record Official record
Conditions
Eczema
Interventions
hydrogel patch, Triamcinolone (TAC) 0.1% cream
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT02260986
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo (for Dupilumab), Topical Corticosteroid (TCS)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

Topical Steroid Formulation and Wet Wraps

NCT02680301
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
0.1% triamcinolone CREAM, 0.1% triamcinolone OINTMENT
Drug
Lead sponsor
Seton Healthcare Family
Other
Eligibility
3 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Early Phase 1 Interventional

Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis

NCT04036188
View directory record Official record
Conditions
Plaque Psoriasis, Vitamin D3
Interventions
Triamcinolone, Vitamin D3, Placebo
Drug · Dietary Supplement
Lead sponsor
Wright State University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

NCT03345914
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Matching Placebo, Background Treatment: Topical Corticosteroids, Background Treatment: Moisturizers
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis

NCT00021294
View directory record Official record
Conditions
Non-melanomatous Skin Cancer, Precancerous/Nonmalignant Condition
Interventions
eflornithine, triamcinolone
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus

NCT06748404
View directory record Official record
Conditions
Immunotherapy-related Pruritus
Interventions
TriCalm Hydrogel®, Triamcinolone acetonide 0.1% cream
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption

NCT03115567
View directory record Official record
Conditions
Acneiform Rash, Papulopustular Eruption
Interventions
Triamcinolone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial

NCT00847912
View directory record Official record
Conditions
Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Skin Neoplasms, Skin Diseases, Neoplasms, Basal Cell, Neoplasms, Squamous Cell, Carcinoma
Interventions
5-fluorouracil, Placebo, vehicle control
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
954 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
13
States / cities
Palo Alto, California • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 17, 2026, 5:15 AM EDT